ArticleCell journal2022
The Global mRNA Expression Profiles of Inhibiting PHGDH Induced Cisplatin Resistance in Gastric Cancer.
Article in Cell journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood metabolites and gastric cancer risk: A bidirectional 2-sample Mendelian randomization study.Medicine · 2025Article
- Serine metabolism in tumor progression and immunotherapy.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<strong>Objective</strong>: Drug resistance is the main hindrance to improve the prognosis of patients with gastric cancer. Amino<br />acid metabolic reprograming is essential to satisfy the different requirements of cancer cells during drug resistance,<br />of which serine deprivation could promote resistance to cisplatin in gastric cancer. As the key enzyme in the de novo<br />biosynthesis of serine, phosphoglycerate dehydrogenase (PHGDH) inhibition could also induce cisplatin resistance in<br />gastric cancer. This study aims to reveal the potential mechanisms of drug resistance induced by PHGDH inhibition via<br />exploring the global mRNA expression profiles.<br /><strong>Materials and Methods</strong>: In this experimental study, the viability and the apoptotic rate of gastric cancer cells<br />were evaluated by using Cell Counting Kit-8 (CCK-8) analysis and flow cytometric determination, respectively. The<br />identification of differentially expressed genes (DEGs) was tested by mRNA-sequencing (mRNA-Seq) analysis. The<br />confirmation of sequencing results was verified using real-time quantitative reverse transcription polymerase chain<br />reaction (RT-qPCR).<br /><strong>Results:</strong> The inhibition of PHGDH significantly increased the viability and decreased the apoptotic rate induced by cisplatin<br />in gastric cancer cells. mRNA-Seq analysis revealed that the combined treatment of NCT503 reduced the number of DEGs<br />induced by cisplatin. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment<br />Analysis (GSEA) showed that unfolded protein response, ECM receptor interaction and cell cycle signaling pathways were<br />modulated by NCT503 treatment. Hub genes were identified by using protein-protein interaction network modeling, of which E1A binding protein p300 (EP300) and heat shock protein family A (Hsp70) member 8 (HSPA8) act as the vital genes in cisplatin resistance induced by the inhibition of PHGDH.<br /><strong>Conclusion:</strong> These findings suggested that the inhibition of PHGDH promoted cisplatin resistance in gastric cancer<br />through various intercellular mechanisms. And appropriate serine supplementation or the modulation of EP300 and<br />HSPA8 may be of great help in overcoming cisplatin resistance in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.